Stromal vascular fraction-enriched fat grafting as treatment of adherent scars: study design of a non-randomized early phase trial

被引：0
|
作者：
Linda Vriend
Joris A. van Dongen
Anouk Pijpe
Marianne K. Nieuwenhuis
Sandra J. M. Jongen
Martin C. Harmsen
Paul P. M. van Zuijlen
Berend van der Lei
机构：
[1] University of Groningen,Department of Pathology & Medical Biology
[2] University Medical Center Groningen,Department of Plastic Surgery
[3] University of Groningen and University Medical Center of Groningen,Department of Plastic Surgery
[4] University of Utrecht,Burn Center
[5] and University Medical Center Utrecht,Association of Dutch Burn Centers
[6] Red Cross Hospital,Department of Plastic, Reconstructive and Hand Surgery
[7] Red Cross Hospital,Association of Dutch Burn Centers
[8] Amsterdam UMC,Research Group Healthy Ageing, Allied Health Care and Nursing
[9] Vrije Universiteit Amsterdam,Department of Human Movement Sciences
[10] Amsterdam Movement Sciences,Pediatric Surgical Centre, Emma Children’s Hospital
[11] Martini Hospital,undefined
[12] Hanze University of Applied Sciences,undefined
[13] University Medical Center Groningen,undefined
[14] Amsterdam UMC,undefined
[15] University of Amsterdam,undefined
[16] Vrije Universiteit,undefined
[17] Bergman Clinics,undefined
[18] Bergman Clinics,undefined
来源：
Trials | / 23卷
关键词：
Adherent scars; Scar quality; Burn scars; Stromal vascular fraction; Adipose-derived stromal cells; ASC; Fat grafting; Pliability;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 31 条
  • [21] Randomized phase III trial evaluating the role of weight loss in adjuvant treatment of overweight and obese women with early breast cancer (Alliance A011401): study design
    Ligibel, Jennifer A.
    Barry, William T.
    Alfano, Catherine
    Hershman, Dawn L.
    Irwin, Melinda
    Neuhouser, Marian
    Thomson, Cynthia A.
    Delahanty, Linda
    Frank, Elizabeth
    Spears, Patty
    Paskett, Electra D.
    Hopkins, Judith
    Bernstein, Vanessa
    Stearns, Vered
    White, Julia
    Hahn, Olwen
    Hudis, Clifford
    Winer, Eric P.
    Wadden, Thomas A.
    Goodwin, Pamela J.
    NPJ BREAST CANCER, 2017, 3
  • [22] Randomized phase III trial evaluating the role of weight loss in adjuvant treatment of overweight and obese women with early breast cancer (Alliance A011401): study design
    Jennifer A. Ligibel
    William T. Barry
    Catherine Alfano
    Dawn L. Hershman
    Melinda Irwin
    Marian Neuhouser
    Cynthia A. Thomson
    Linda Delahanty
    Elizabeth Frank
    Patty Spears
    Electra D. Paskett
    Judith Hopkins
    Vanessa Bernstein
    Vered Stearns
    Julia White
    Olwen Hahn
    Clifford Hudis
    Eric P. Winer
    Thomas A. Wadden
    Pamela J. Goodwin
    npj Breast Cancer, 3
  • [23] A phase II multicenter, open label, non-randomized study of neoadjuvant and adjuvant treatment with IPH5201 and durvalumab in patients with resectable, early-stage (II to IIIA) non-small cell lung cancer (MATISSE)
    Barlesi, F.
    Mercier, O.
    Lowczak, A.
    Mandziuk, S.
    Kuzdzal, J.
    Koutras, A.
    Dasgupta, A.
    Leyco, A. J.
    Andre, P.
    Mager, R.
    Fraenkel, P. G.
    Paturel, C. L.
    Chammard, A. Boyer
    ANNALS OF ONCOLOGY, 2023, 34 : S744 - S744
  • [24] Open Label Non-Randomized Phase II Study Exploring "Chemo-Free" Treatment Association with Idelalisib plus Obinutuzumab in Patients with Relapsed/Refractory (R/R) Waldenstrom's Macroglobulinemia (MW), a Filo Trial: Results of the Intermediary Analysis of the Induction Phase
    Tomowiak, Cecile
    Desseaux, Kristell
    Poulain, Stephanie
    Herbaux, Charles
    Perrot, Aurore
    Mahe, Beatrice
    Morel, Pierre
    Tournilhac, Olivier
    Lepretre, Stephane
    Aurran, Therese
    Villemagne, Bruno
    Casasnovas, Olivier
    Nollet, Delphine
    Dreyfus, Brigitte
    Chevret, Sylvie
    Leblond, Veronique
    BLOOD, 2019, 134
  • [25] Neoadjuvant Therapy with Weekly Nanoparticle Albumin-Bound Paclitaxel for Luminal Early Breast Cancer Patients: Results from the NABRAX Study (GEICAM/2011-02), a Multicenter, Non-Randomized, Phase II Trial, with a Companion Biomarker Analysis
    Martin, Miguel
    Chacon, Jose I.
    Anton, Antonio
    Plazaola, Arrate
    Garcia-Martinez, Elena
    Segui, Miguel A.
    Sanchez-Rovira, Pedro
    Palacios, Jose
    Calvo, Lourdes
    Esteban, Carmen
    Espinosa, Enrique
    Barnadas, Agusti
    Batista, Norberto
    Guerrero, Angel
    Munoz, Montserrat
    Romio, Estefania
    Rodriguez-Martin, Cesar
    Caballero, Rosalia
    Casas, Maria I.
    Rojo, Federico
    Carrasco, Eva
    Antolin, Silvia
    ONCOLOGIST, 2017, 22 (11): : 1301 - 1308
  • [26] A Phase II Multi-Center, Non-Randomized, Parallel Group, Non-Inferiority Study to Compare the Efficacy of No Radioactive Iodine Remnant Ablation to Remnant Ablation Treatment in Low- to Intermediate-Risk of Papillary Thyroid Cancer: The MOREthyroid Trial Protocol
    Lee, Eun Kyung
    Lee, You Jin
    Park, Young Joo
    Moon, Jae Hoon
    Yi, Ka Hee
    Kim, Koon Soon
    Lee, Joo Hee
    Cho, Sun Wook
    Joo, Jungnam
    Hwangbo, Yul
    Go, Sujeong
    Park, Do Joon
    ENDOCRINOLOGY AND METABOLISM, 2020, 35 (03) : 571 - 577
  • [27] TREATMENT RATIONALE AND STUDY DESIGN FOR AN OPEN-LABEL RANDOMIZED PHASE II TRIAL OF GEMCITABINE AND CISPLATIN WITH OR WITHOUT BEVACIZUMAB IN EGFR WILD-TYPE NON-SQUAMOUS NON-SMALL-CELL LUNG CANCER
    Li, Juan
    Yu, Ping
    Liu, Bin
    Yang, Ye
    Liu, Xiaoqin
    Wen, Yan
    Tan, Xiaohui
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S590 - S590
  • [28] The Early Glycoprotein IIb/IIIa Inhibition in Non-ST-Segment Elevation Acute Coronary Syndrome (EARLY ACS) trial: A randomized placebo-controlled trial evaluating the clinical benefits of early front-loaded-eptifibatide in the treatment of patients with non-ST-segment elevation acute coronary syndrome - Study design and rationale
    Giugliano, RP
    Newby, LK
    Harrington, RA
    Gibson, CM
    Van de Werf, F
    Armstrong, P
    Montalescot, G
    Gilbert, J
    Strony, JT
    Califf, RM
    Braunwald, E
    AMERICAN HEART JOURNAL, 2005, 149 (06) : 994 - 1002
  • [29] Rationale for Treatment and Study Design of TAILOR: A Randomized Phase III Trial of Second-line Erlotinib Versus Docetaxel in the Treatment of Patients Affected by Advanced Non-Small-Cell Lung Cancer With the Absence of Epidermal Growth Factor Receptor Mutations
    Farina, Gabriella
    Longo, Flavia
    Martelli, Olga
    Pavese, Ida
    Mancuso, Andrea
    Moscetti, Luca
    Labianca, Roberto
    Bertolini, Alessandro
    Cortesi, Enrico
    Farris, Antonio
    Fagnani, Daniele
    Locatelli, Maria Cristina
    Valmadre, Giuseppe
    Ardizzoia, Antonio
    Tomirotti, Maurizio
    Rulli, Eliana
    Garassino, Marina Chiara
    Scanni, Alberto
    CLINICAL LUNG CANCER, 2011, 12 (02) : 138 - 141
  • [30] Treatment Rationale Study Design for the MetLung Trial: A Randomized, Double-Blind Phase III Study of Onartuzumab (MetMAb) in Combination With Erlotinib Versus Erlotinib Alone in Patients Who Have Received Standard Chemotherapy for Stage IIIB or IV Met-Positive Non-Small-Cell Lung Cancer
    Spigel, David R.
    Edelman, Martin J.
    Mok, Tony
    O'Byrne, Kenneth
    Paz-Ares, Luis
    Yu, Wei
    Rittweger, Karen
    Thurm, Holger
    CLINICAL LUNG CANCER, 2012, 13 (06) : 500 - 504
1234